Despite its promise, targeting CD47 in cancer therapy presents several challenges. One major concern is the potential for toxicity, as CD47 is expressed on normal cells as well. This can lead to unwanted side effects, such as anemia due to the destruction of red blood cells. Therefore, careful consideration and optimization of dosing and delivery methods are crucial.
